Alzinova AB (publ)

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study. The company has a research collaboration with Amsterdam University Medical Center to develop a blood‑based test that measures naturally occurring antibodies against toxic amyloid‑β oligomers. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden.